Coherus Oncology, Inc. (NASDAQ:CHRS) Sees Significant Decline in Short Interest

Coherus Oncology, Inc. (NASDAQ:CHRS) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 12,452,177 shares, a drop of 46.6% from the September 30th total of 23,337,539 shares. Currently, 8.7% of the company’s shares are sold short. Based on an average daily trading volume, of 1,579,236 shares, the days-to-cover ratio is presently 7.9 days.

Key Coherus Oncology News

Here are the key news stories impacting Coherus Oncology this week:

• Positive Sentiment: HC Wainwright initiated coverage of Coherus Oncology with a Buy rating, signaling confidence in the biotechnology company’s longer-term prospects. The analyst projects losses narrowing from $0.91 per share in fiscal 2026 to $0.63 in fiscal 2027, $0.19 in fiscal 2029, and a return to positive earnings of $0.19 per share in fiscal 2030. HC Wainwright Initiates Coverage on Coherus Oncology
• Positive Sentiment: Early data from Coherus’s oncology program reportedly showed encouraging results in esophageal squamous cell carcinoma (ESCC), offering a possible development catalyst. However, investors are questioning whether the results can support additional indications. Early data good in ESCC, but can Coherus tagmo indications?
• Neutral Sentiment: HC Wainwright’s detailed forecasts call for quarterly losses of $0.22 per share in Q3 2026, $0.21 in Q4 2026, and approximately $0.17 to $0.13 per share through 2027. The estimates indicate gradual improvement, but not near-term profitability. Coherus Oncology analyst estimates
• Negative Sentiment: The company is still expected to report substantial losses, with HC Wainwright’s fiscal 2026 estimate of a $0.91 per-share loss slightly worse than the $0.87 consensus estimate. Persistent losses and uncertainty over expanding the ESCC data into broader indications likely weigh on investor sentiment.

Coherus Oncology Trading Down 7.6%

CHRS stock traded down $0.07 during trading on Friday, reaching $0.83. The company had a trading volume of 2,185,506 shares, compared to its average volume of 1,595,360. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.77 and a quick ratio of 1.70. Coherus Oncology has a 52 week low of $0.81 and a 52 week high of $2.62. The business has a 50 day moving average of $1.20 and a 200 day moving average of $1.53. The company has a market cap of $128.25 million, a P/E ratio of -0.81 and a beta of 0.98.

Coherus Oncology (NASDAQ:CHRS) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.06. The business had revenue of $14.31 million for the quarter, compared to analysts’ expectations of $14.41 million. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%. As a group, sell-side analysts forecast that Coherus Oncology will post -0.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CHRS. Spark Investment Management LLC bought a new stake in shares of Coherus Oncology during the second quarter valued at approximately $25,000. Cetera Investment Advisers purchased a new stake in Coherus Oncology in the first quarter worth $54,000. Dimensional Fund Advisors LP purchased a new stake in Coherus Oncology in the first quarter worth $60,000. The Manufacturers Life Insurance Company bought a new position in Coherus Oncology in the second quarter worth $54,000. Finally, Hsbc Holdings PLC bought a new position in Coherus Oncology in the second quarter worth $131,000. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on CHRS. Weiss Ratings raised Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. HC Wainwright assumed coverage on Coherus Oncology in a report on Thursday. They set a “buy” rating for the company. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $11.00.

Coherus Oncology Company Profile

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.